Loading…
Loading…
AIFF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AIFF and 80,000+ other tickers.
See exactly how AIFF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AIFF and 80,000+ other tickers.
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and…
Pro Medicus (OTCMKTS:PMCUF - Get Free Report) and Firefly Neuroscience (NASDAQ: AIFF - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings. Insider and Institutional Ownership 5.0% of Firefly Neuroscience
KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™.
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –
– Comes just weeks after Firefly confirmed its active public-private partnership with the U.S. Department of War – KENMORE, N.Y, June 02, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company advancing precision neuroscience, today announced the identification of a novel electrophysiological biomarker for Post-Traumatic Stress Disorder (“PTSD”) using brain scans collected on its FDA-510(k)-cleared Evoke System. The biomarker discovery emanates partly from Firefly's previously announced public-private partnership with the U.S. Department of War (“DoW”) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury (“TBI”).
Firefly Neuroscience, Inc. (NASDAQ: AIFF - Get Free Report) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 1,324,628 shares, a decline of 14.6% from the March 15th total of 1,551,962 shares. Currently, 9.6% of the company's shares are sold short.